Hubei Goto Biopharm

What Hubei Goto Biopharm does

Hubei Goto Biopharm (湖北共同药业集团股份有限公司, Shenzhen Stock Exchange: 300966.SZ) is a Chinese specialty pharmaceutical manufacturer founded in 2006 and headquartered in Xiangyang, Hubei. The company develops, produces and sells steroid hormone starting materials and intermediates, anchored by a biological fermentation platform that converts plant sterols into core steroid precursors including androstenedione, 9α-hydroxyandrostenedione, and 1,4-androstadienedione. With 3,000 tons of annual starting-material capacity and over 60% domestic market share, Goto supplies the upstream feedstocks for sex hormones, progestogens, corticosteroids and other steroid drug classes used by global pharmaceutical manufacturers. Its 100+ SKU intermediate portfolio spans sexual hormones (testosterone, estradiol, nandrolone), progestogens (progesterone), corticosteroids (prednisone acetate) and other steroid derivatives.

The company generates revenue through a B2B direct sales model targeting global pharmaceutical manufacturers, with international sales rising from 28.54% of revenue in 2024 to 38.6% in H1 2025 and a stated target of 60-70% overseas contribution. Distribution is supported by international trade show participation (CPHI Worldwide, API China), overseas subsidiaries and a custom manufacturing workshop (OEM/CMO) achieving 50%+ gross margins for international clients. The company operates two production bases in Hubei (Danjiangkou and Yicheng), an R&D institute in Wuhan, and a strategic joint venture (Hubei Huahai Goto Pharmaceutical, established May 2020 with Zhejiang Huahai Pharmaceutical) targeting 30-50 globally certified high-end steroid APIs.

Goto is moving down the value chain from intermediates into finished APIs, evidenced by a 500M RMB investment in the Vitamin and High-End Steroid API Project in Yicheng and the Huahai Goto JV's full-range steroid API strategy. Recognition includes national-level Specialized & Innovative "Little Giant" enterprise status (recertified 2025), Hubei Province Manufacturing Single-Item Champion for androstenedione (2024), and Hubei Province pillar-industry hidden champion enterprise (2018-2020). The chairman, Xi Zubin, holds National "Ten Thousand Plan" talent designation and multiple provincial science and technology progress awards.

Name

Hubei Goto Biopharm

Legal name

湖北共同药业集团股份有限公司

Website

https://gotopharm.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Hubei Goto Biopharm is a Chinese publicly listed manufacturer (300966.SZ) that produces steroid hormone starting materials and intermediates via biological fermentation, serving global pharmaceutical manufacturers with a 3,000-ton capacity and 100+ SKU portfolio.

Ownership category

akta.pro rank

Product category

Pharmaceutical Ingredients (Steroid Hormone APIs and Intermediates)

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Steroid hormone intermediates
• Pharmaceutical raw materials
• Active pharmaceutical ingredients
• Biological fermentation manufacturing
• Steroid API production

Headquarters

HQ city

Xiangyang

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Steroid Starting Materials Sales: Sale of steroid starting materials including androstenedione, androstadienedione, and 9-hydroxyandrostenedione to pharmaceutical manufacturers worldwide
2. Steroid Intermediate Sales: Production and sale of 100+ steroid intermediate products covering sexual hormones, progestogens, corticosteroids and other steroid categories
3. Custom Manufacturing Services (OEM/CMO): Contract manufacturing services for international pharmaceutical companies with dedicated workshop achieving 50%+ gross margin. Custom production of steroid drugs per client specifications
4. Active Pharmaceutical Ingredients (API): Production of high-end steroid APIs including 13高端原料药品种 under Huaihai Goto subsidiary. Target of 30-50 globally certified API varieties

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Hubei Goto Biopharm manufactures and sells steroid hormone pharmaceutical starting materials and intermediates using proprietary biological fermentation technology. The company produces over 100 steroid compounds across three tiers: starting materials (androstenedione, androstadienedione, 9-hydroxyandrostenedione), intermediates (sex hormones, progestogens, corticosteroids), and high-end active pharmaceutical ingredients (APIs) developed through the Hubei Huahai Goto joint venture. Core offerings are sold directly to global pharmaceutical manufacturers for use in steroid drug production.

Product overview

Hubei Goto Biopharm is a comprehensive high-tech enterprise specializing in the R&D, production, and sales of steroid hormone raw materials and intermediates. The company's product portfolio consists of three main tiers: (1) Starting Materials produced via biological fermentation technology including androstenedione, 9-hydroxy-androstenedione, and androstadienedione with 3,000-ton annual capacity and over 60% market share; (2) Intermediates spanning sex hormones (testosterone, estradiol, nandrolone), progestogens (progesterone), corticosteroids (prednisone acetate, cortisone acetate), and other steroid derivatives—totaling over 100 product varieties; (3) Downstream API expansion through the Huahai Goto joint venture and the new Vitamin & High-End Steroid API project (500 million RMB investment). The company operates from two production bases in Hubei Province and serves global pharmaceutical customers across Europe, America, and Southeast Asia.

Differentiator

Problem solved

Functional benefit

Products and services

• 4-Androstenedione (4-雄烯二酮) Key starting material for steroid hormone synthesis, used as a precursor for producing various sex hormones and corticosteroids. Sold to pharmaceutical manufacturers.
• 9a-Hydroxy-4-Androstenedione (9a-羟基-4-雄烯二酮) Hydroxylated starting material for corticosteroid and sex hormone production via fermentation. Sold to pharmaceutical manufacturers.
• 1,4-Androstadienedione (1.4-雄二烯二酮) Intermediate for steroid drug synthesis produced through plant sterol fermentation. Sold to pharmaceutical manufacturers.
• Progesterone (黄体酮) Progestogen hormone intermediate used in reproductive health applications, produced as a key intermediate in the steroid drug chain. Sold to pharmaceutical manufacturers.
• Prednisone Acetate (醋酸泼尼松) Corticosteroid intermediate for anti-inflammatory drug manufacturing. Sold to pharmaceutical manufacturers.
• Estradiol (雌二醇) Estrogen hormone intermediate for hormone replacement therapy and other pharmaceutical applications. Sold to pharmaceutical manufacturers.
• Nandrolone (诺龙) Anabolic steroid intermediate for various pharmaceutical applications. Sold to pharmaceutical manufacturers.
• Testosterone (睾酮) Male sex hormone intermediate for pharmaceutical synthesis. Sold to pharmaceutical manufacturers.
• Ursodeoxycholic Acid (熊去氧胆酸) Bile acid derivative intermediate used in hepatobiliary disease treatment. Sold to pharmaceutical manufacturers.
• Altrenogest (烯丙孕素) Synthetic progestogen used in veterinary pharmaceutical applications. Sold to pharmaceutical manufacturers.
• Exemestane (依西美坦) Aromatase inhibitor intermediate used in breast cancer treatment pharmaceutical production. Sold to pharmaceutical manufacturers.
• Huahai Goto API Project (华海共同原料药项目) High-end steroid active pharmaceutical ingredients (APIs) produced through the Hubei Huahai Goto joint venture with Zhejiang Huahai Pharmaceutical, covering sex hormones, progestogens, corticosteroids, and other steroid drugs. Sold to pharmaceutical manufacturers globally.
• Vitamin and High-End Steroid API Project (维生素与高端甾体系列原料药及中间体项目) High-end steroid APIs and intermediates production capabilities, including high-purity vitamin series. Major expansion project with 500 million RMB investment in Yicheng to produce 62 tons/year of vitamins and 72 tons/year of high-end steroid APIs and intermediates. Sold to pharmaceutical manufacturers.
• Custom Manufacturing Services (OEM/CMO) Contract manufacturing services for international pharmaceutical companies producing steroid drugs per client specifications. The dedicated custom manufacturing workshop achieves over 50% gross margin for international pharmaceutical company orders.

Quantifiable outcome

• Production capacity of 3000 tons with market share exceeding 60% in steroid starting materials
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Hubei Huahai Goto Pharmaceutical Co., Ltd. (湖北华海共同药业有限公司)coreStrategic or Co-development Partner · 11 September 2020Joint venture company jointly operated by Goto and Huahai, targeting deep cultivation of high-end steroid drug market. Positioned to become China's first integrated provider covering sexual hormones, progestogens, corticosteroids and other steroid APIs across complete product range.
• Hubei University of Technology (湖北工业大学)coreStrategic or Co-development Partner · 21 July 2020Industry-academia-research cooperation agreement signed on July 21, 2020 at Goto's Wuhan Research Institute. Collaboration focuses on joint research and talent development in steroid pharmaceutical technology. Includes shared laboratory facilities and student internship programs.
• Zhejiang Huahai Pharmaceutical Co., Ltd. (浙江华海药业股份有限公司)coreStrategic or Co-development Partner · 13 May 2020Joint venture Hubei Huahai Goto Pharmaceutical Co., Ltd. established on May 13, 2020 to develop high-end steroid APIs. Goto provides technology, production capacity and steroid industry expertise; Huahai contributes quality management systems, EU/US regulatory certifications, and international sales networks. JV targeting 30-50 globally certified API varieties to break current domestic industry ceiling of 30 varieties per company.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Cipla Limited: Global pharmaceutical company with strong API manufacturing capabilities and a presence in respiratory, hormonal, and women's health segments. Comparable as a buyer of steroid APIs/intermediates and as a broader API/pharma incumbent.
• Aspen Pharmacare Holdings Limited: Global generics and API manufacturer with significant presence in steroid hormones and women's health. Comparable as a global incumbent in steroid APIs that competes for similar customers and is active in the same end-market segments.
• Sanofi: Global pharmaceutical major with an established steroid and hormone therapy franchise across corticosteroids and reproductive health. Comparable as a downstream buyer of steroid APIs/intermediates and as a broad incumbent in the same end-markets.
• Lupin Limited: Global pharmaceutical company with significant API manufacturing footprint and presence in women's health and hormone therapeutic categories. Comparable as a global API/pharma incumbent that Goto could supply or compete against for similar end-customers.
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Major Chinese pharmaceutical conglomerate with diversified portfolio across APIs, finished drugs, and diagnostics. Comparable as a Chinese pharma incumbent with global ambitions, but much broader than Goto's steroid-specialist focus.

Direct peers

• Apeloa Pharmaceutical Co., Ltd. Chinese API and intermediate manufacturer with strong fermentation/synthetic biology capabilities. Directly comparable business model (B2B API/intermediates), regulatory positioning, and customer base of pharmaceutical manufacturers.
• Organon & Co. Global women's health specialty pharma company with significant franchise in reproductive health hormones (e.g., fertility, contraception). Comparable as a downstream buyer/customer profile and end-market overlap, particularly for Goto's progesterone and sex hormone intermediates.
• Zhejiang Huahai Pharmaceutical Co., Ltd. Major Chinese pharmaceutical manufacturer with global regulatory certifications and an international sales network, and Goto Biopharm's JV partner in Hubei Huahai Goto Pharmaceutical. Directly comparable in steroid/finished-dose API manufacturing and target customer base.
• Tianjin Tianyao Pharmaceutical Co., Ltd. Chinese steroid and corticosteroid hormone API manufacturer with overlapping product categories (corticosteroids, sex hormones). Comparable in scale, technology base, and customer segments in domestic and international steroid pharma.
• Shandong Xinhua Pharmaceutical Co., Ltd. Large Chinese pharmaceutical manufacturer with significant API and intermediate production across multiple therapeutic categories. Comparable in being a public Chinese API manufacturer serving global pharmaceutical customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/yicheng-goto-pharmaceuticals-co-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hubei Goto Biopharm